Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of tapering strategies after JAK inhibitor response in alopecia areata
ChiCTR2600131224Phase 4Not yet recruiting
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Jun 2026
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of aldesleukin in alopecia areata (3 arms), sponsored by Xiangya Hospital, Central South University. Primary endpoint: Treatment failure rate 12 months after enrollment. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
aldesleukin
03
Conditions
alopecia areata
Beyond the preview
Go deeper on ChiCTR2600131224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131224.